{"id":"ethyl-methyl-hydroxypyridine-succinate-meldonium","safety":{"commonSideEffects":[{"rate":null,"effect":"Gastrointestinal disturbances"},{"rate":null,"effect":"Dizziness"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Allergic reactions"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Ethyl methyl hydroxypyridine succinate (Emoxypine succinate) is an antioxidant that scavenges free radicals and stabilizes cell membranes, while Meldonium enhances mitochondrial energy production by optimizing carnitine metabolism. Together, they improve cellular energy utilization and reduce ischemic damage, particularly in cardiac and cerebral tissues.","oneSentence":"This combination product enhances cellular energy metabolism and reduces oxidative stress through antioxidant and cardioprotective mechanisms.","_ai_confidence":"low"},"_scrapedAt":"2026-03-27T23:45:59.746Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute myocardial infarction"},{"name":"Chronic heart failure"},{"name":"Cerebrovascular disease"},{"name":"Angina pectoris"}]},"trialDetails":[{"nctId":"NCT05939622","phase":"PHASE4","title":"Efficacy of the Therapy With BRAINMAX® Using fMRI for the Treatment of Patients With Asthenia After COVID-19","status":"COMPLETED","sponsor":"Promomed, LLC","startDate":"2022-05-18","conditions":"Asthenia, COVID-19, Functional MRI","enrollment":30},{"nctId":"NCT05689827","phase":"PHASE4","title":"Safety and Efficacy of the Therapy With BRAINMAX® for the Treatment of Patients With Asthenia After COVID-19","status":"COMPLETED","sponsor":"Promomed, LLC","startDate":"2022-04-05","conditions":"Asthenia, COVID-19","enrollment":160}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["BRAINMAX®"],"phase":"marketed","status":"active","brandName":"Ethyl methyl hydroxypyridine succinate + Meldonium","genericName":"Ethyl methyl hydroxypyridine succinate + Meldonium","companyName":"Promomed, LLC","companyId":"promomed-llc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This combination product enhances cellular energy metabolism and reduces oxidative stress through antioxidant and cardioprotective mechanisms. Used for Acute myocardial infarction, Chronic heart failure, Cerebrovascular disease.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}